Loading…
Loading…
ADIA does not currently pay a dividend.
See exactly how ADIA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ADIA and 80,000+ other tickers.
Adia Med Inc. is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, while Adia Labs manufactures and distributes regenerative products. The company is also involved in multiple Institutional Review Board (IRB)-approved clinical studies.
Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market. Lucosky Brookman LLP To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC"), conducting necessary due diligence related to the registration statement, preparation and filing of responses to SEC comments and any related amendments, preparation and filing of the Company's application for listing of its securities on a nationally recognized securities exchange (including responses to comments and amendments), and assisting with general corporate matters related to the registration statement and listing application.
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission. Inline Viewer: ADIA NUTRITION, INC.
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m.
Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives.
Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the study's ongoing, staggered enrollment schedule.